paricalcitol
information and resources from the National Cancer Institute
paricalcitol
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. paricalcitol
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes.
|
|
|
|
news articles
Calcitriol and QW-1624-F2-2 are promising for prevention of ... Nov 20, 2005
Xagena.it, Park Cancer Institute conducted both in vitro and in vivo studies to determine the effects of Calcitriol and the analogs, QW-1624-F2-2 and Paricalcitol, on the ...
Calcitriol and QW-1624-F2-2 are promising for prevention of ... Nov 20, 2005
Xagena.it, Park Cancer Institute conducted both in vitro and in vivo studies to determine the effects of Calcitriol and the analogs, QW-1624-F2-2 and Paricalcitol, on the ...
|
|
